Enveric Biosciences, Inc. (ENVB) Stock Price & Analysis
Enveric Biosciences, Inc. (ENVB) fell 2.27% to USD 1.29 as of July 25, 2026 at 04:49 UTC, according to Nexqual real-time market data.
ENVB last closed at USD 1.32; the session ranged USD 1.25–1.31 on volume of 103,122 shares. Market capitalization is $5.20M, with a 52-week range of USD 1.25–17.64 (NCM). Source: Nexqual, July 25, 2026 at 04:49 UTC.
Key Statistics (as of July 25, 2026 at 04:49 UTC)
| Price | USD 1.29 |
|---|---|
| Change | ▼ 2.27% (down) |
| Previous Close | USD 1.32 |
| Open | USD 1.3 |
| Day Range | USD 1.25 – 1.31 |
| 52-Week Range | USD 1.25 – 17.64 |
| Volume | 103,122 shares |
| Market Cap | $5.20M |
| Exchange | NCM |
Technical Analysis (ENVB)
Nexqual's technical model rates ENVB "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.03 (neutral) |
| vs SMA50 | Below (USD 1.67) |
| MACD | -0.11 (negative) |
Analyst Ratings (ENVB)
Wall Street analysts rate ENVB "None", per Nexqual as of July 25, 2026 at 04:49 UTC.
| Consensus Rating | None |
|---|
Earnings (ENVB)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD -2.03 vs est -2.76 ▲ beat |
| 2024-06-30 | USD -45 vs est -99 ▲ beat |
| 2024-03-31 | USD -109.8 vs est -139.5 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financials & Fundamentals (ENVB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -183.12% |
| Current Ratio | 11.67 |
| Total Cash | $4.91M |
| Total Debt | $0 |
| Free Cash Flow | $-4.91M |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financial Health Score (ENVB)
Nexqual rates Enveric Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $5M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -183%, ROA -96.7% |
Ownership (ENVB)
| Insider Ownership | +10.81% |
|---|---|
| Institutional Ownership | +2.93% |
| Shares Outstanding | 4.03M |
| Float | 3.54M |
| Short % of Float | +0.39% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Leadership (ENVB)
Enveric Biosciences, Inc. is led by Joseph Edward Tucker (age 56), CEO & Director, per Nexqual as of July 25, 2026 at 04:49 UTC.
| CEO & Director | Joseph Edward Tucker (age 56) |
|---|---|
| Chief Financial Officer | Kevin M. Coveney (age 61) |
Major Backers & Investors (ENVB)
Notable institutional backers of Enveric Biosciences, Inc. include AdvisorShares Trust-AdvisorShares Psychedelics ETF, AdvisorShares Investments, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 04:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.96% |
| AdvisorShares Investments, LLC | 0.46% |
| Fidelity | 0.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.87% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
From Enveric Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- The conduct of the pre-clinical tests must comply with federal regulations, including the FDA's Good Laboratory Practices regulations and the U.S.
- While we believe that our technology, knowledge and experience as well as the scientific resources at our disposal provide us with significant competitive advantages, we face potential competition from many different sources.
Partnerships
- Competitors may use this publicly available information to gain knowledge regarding the design and progress of our development programs.   Special Protocol Assessment   A company may reach an agreement with the FDA under the Special Protocol Assessment, or "SPA", process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim.
- Enveric is a neuro-pharmaceutical scientific company and as such we do not advocate for the legalization of psychedelic substances nor do we deal with psychedelic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADTX | Aditxt, Inc. | USD 0 | ▲ 33.33% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| PALI | Palisade Bio, Inc. | USD 1.95 | ▲ 2.63% |
| RKTO | Rocket One Inc. | USD 0.79 | ▼ 4.35% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.04 | ▼ 1.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:49 UTC. This page is informational and not investment advice.